Market Overview:
The global dermatophytic onychomycosis market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of fungal nail infections, rising awareness about available treatment options, and growing demand for topical and oral antifungal drugs. Based on type, the global dermatophytic onychomycosis market is segmented into oral and topical. The oral segment is expected to account for the majority share of the market in 2018 owing to high efficacy and better patient compliance as compared to topical drugs. However, the topical segment is projected to grow at a higher CAGR during the forecast period due its ease of use and lower side effects as compared with oral drugs. Based on application, hospitals are estimated to account for majority share of global dermatophytic onychomycosis market in 2018 followed by clinics & laboratories and others segments respectively.
Product Definition:
Dermatophytic onychomycosis is a fungal infection of the nails. It is caused by dermatophytes, a type of fungus that can cause skin, hair, and nail infections. The fungus invades the nail bed and causes the nail to become thickened and discolored. The infection can also cause pain and discomfort in the toes or fingers. Dermatophytic onychomycosis is a common infection, especially in people who are frequently exposed to moisture or who have weakened immune systems.
Oral:
Oral onychomycosis is a fungal infection of the nail. It is one of the most common infections in patients with diabetes mellitus and immunosuppressed patients. The prevalence rate of oral onychomycosis ranges from 2% to 10% depending upon the population studied, geographic location, and other relevant factors.
The high prevalence rate coupled with rising awareness levels among affected individuals has led to an increase in research activities for better diagnosis.
Topical:
Topical antifungal medication is used to treat onychomycosis, a fungal infection of the skin. Onychomycosis has been categorized into two types: systemic and localized or cutaneous. The most common form of the disease is cutaneous, which includes nail infections and palmoplantar keratitis. However, in some cases nail infections may spread to other parts of the body such as foot & ankle or even become life-threatening.
Application Insights:
Onychomycosis is a common skin disease that mostly affects the aged population. The application segment of the global dermatophytic onychomycosis market is categorized into hospitals, clinics and laboratories, and others. Hospitals held the largest share of this market in 2017 due to high prevalence rates of onychomycosis patients in hospitals as compared to other application settings. Dermatology outpatient clinics are also one of the major treatment sites for this infection owing to their accessibility and ease of management for patients with busy schedules.
The others segment includes independent medical centers (IMCs) and other healthcare facilities such as Ambulatory Surgical Centers (ASCs).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing awareness about onychomycosis, availability of effective treatment options, and high disposable income of patients in this region. Moreover, presence of key players such as Johnson & Johnson Services LLC; Ortho Dermatologics; and Merz Pharma GmbH & Co., KGaA will also help boost growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the next eight years owing to rising patient awareness levels coupled with improving healthcare infrastructure especially in developing countries such as India and China.
Growth Factors:
- Increasing incidence of onychomycosis
- Growing awareness about the disease and its treatment options
- Rising prevalence of diabetes and other underlying medical conditions that predispose to onychomycosis
- Proliferation of at-home treatment options for onychomycosis
- Increased research and development activities focused on new therapies for onychomycosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Dermatophytic Onychomycosis Market Research Report
By Type
Oral, Topical
By Application
Hospitals, Clinics and laboratories, Others
By Companies
Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis, Valeant Pharmaceuticals, Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, Viamet Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Dermatophytic Onychomycosis Market Report Segments:
The global Dermatophytic Onychomycosis market is segmented on the basis of:
Types
Oral, Topical
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics and laboratories, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Anacor Pharmaceuticals
- Galderma
- Janssen Biotech
- Novartis
- Valeant Pharmaceuticals
- Abeona Therapeutics
- Allergan
- Elorac
- GlaxoSmithKline
- Hexima
- Hisamitsu Pharmaceutical
- Mayne Pharma
- MediQuest Therapeutics
- Meiji Seika Pharma
- Merz Pharma
- Moberg Pharma
- NanoBio
- NovaBiotics
- Nuvo Research
- Pfizer
- Polichem
- Promius Pharma
- Sanofi
- Seren Pharmaceuticals
- Taro Pharmaceutical
- Topica Pharmaceuticals
- Viamet Pharmaceuticals
Highlights of The Dermatophytic Onychomycosis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Topical
- By Application:
- Hospitals
- Clinics and laboratories
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dermatophytic Onychomycosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dermatophytic onychomycosis is a fungal infection of the skin that most often affects the nails. The fungus grows on the surface of the nail and can cause it to become thick, discolored, and brittle. Dermatophytic onychomycosis may also lead to inflammation and pain in the nail bed.
Some of the major companies in the dermatophytic onychomycosis market are Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis, Valeant Pharmaceuticals, Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, Viamet Pharmaceuticals.
The dermatophytic onychomycosis market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dermatophytic Onychomycosis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dermatophytic Onychomycosis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dermatophytic Onychomycosis Market - Supply Chain
4.5. Global Dermatophytic Onychomycosis Market Forecast
4.5.1. Dermatophytic Onychomycosis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dermatophytic Onychomycosis Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dermatophytic Onychomycosis Market Absolute $ Opportunity
5. Global Dermatophytic Onychomycosis Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dermatophytic Onychomycosis Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Topical
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dermatophytic Onychomycosis Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dermatophytic Onychomycosis Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics and laboratories
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dermatophytic Onychomycosis Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dermatophytic Onychomycosis Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dermatophytic Onychomycosis Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dermatophytic Onychomycosis Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dermatophytic Onychomycosis Demand Share Forecast, 2019-2026
9. North America Dermatophytic Onychomycosis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dermatophytic Onychomycosis Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dermatophytic Onychomycosis Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics and laboratories
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dermatophytic Onychomycosis Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Topical
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dermatophytic Onychomycosis Demand Share Forecast, 2019-2026
10. Latin America Dermatophytic Onychomycosis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dermatophytic Onychomycosis Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dermatophytic Onychomycosis Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics and laboratories
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dermatophytic Onychomycosis Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Topical
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dermatophytic Onychomycosis Demand Share Forecast, 2019-2026
11. Europe Dermatophytic Onychomycosis Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dermatophytic Onychomycosis Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dermatophytic Onychomycosis Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics and laboratories
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Dermatophytic Onychomycosis Market Size and Volume Forecast by Type
11.7.1. Oral
11.7.2. Topical
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projectionsby Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dermatophytic Onychomycosis Demand Share, 2019-2026
12. Asia Pacific Dermatophytic Onychomycosis Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dermatophytic Onychomycosis Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dermatophytic Onychomycosis Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics and laboratories
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dermatophytic Onychomycosis Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Topical
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dermatophytic Onychomycosis Demand Share, 2019-2026
13. Middle East & Africa Dermatophytic Onychomycosis Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dermatophytic Onychomycosis Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dermatophytic Onychomycosis Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics and laboratories
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dermatophytic Onychomycosis Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Topical
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dermatophytic Onychomycosis Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dermatophytic Onychomycosis Market: Market Share Analysis
14.2. Dermatophytic Onychomycosis Distributors and Customers
14.3. Dermatophytic Onychomycosis Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Anacor Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Galderma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Janssen Biotech
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Valeant Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Abeona Therapeutics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Allergan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Elorac
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hexima
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hisamitsu Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Mayne Pharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. MediQuest Therapeutics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Meiji Seika Pharma
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Merz Pharma
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Moberg Pharma
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. NanoBio
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. NovaBiotics
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Nuvo Research
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Pfizer
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
